我院抗骨质疏松药物应用情况分析

目的：通过对比分析我院抗骨质疏松（OP）药物在老年病门诊患者及全院的应用数据，为临床用药提供参考。方法：采用抗菌药物的用药频度（DDDs）、用药金额排序、限定日费用等药物经济学参数，对我院2010-2011年老年病门诊患者和全院抗OP药物处方进行回顾性分析。结果：与2010年比较，2011年抗OP药物总消费金额增长幅度（62.37%）远大于其他药品（7.90%），双膦酸盐类药物和钙制剂临床用药量较为平稳，但所占份额均有所下降，维生素D及活性代谢物和降钙素类药物应用量增幅较为突出；老年病门诊患者抗OP用药消耗金额与DDDs数据同步性较好，患者治疗费用更合理，而全院消耗金额与DDDs数据同步性较差；全院及老年病门诊双膦酸盐类药物和活性维生素D类的DDDs及销售金额均最高；阿法骨化醇DDDs明显大于骨化三醇，患者长期应用过程中更具有药物经济学比较优势，有助于提高患者用药依从性。结论：抗OP药物的药物经济学分析和用药趋势调查，应针对临床实际，在进行相关疾病治疗药物分析时采集专业科室的数据更能反映其临床应用的合理性。

Analysis on the Application of Anti-osteoporosis Drugs in Our Hospital

Objective：The comparison and analysis were conducted of the application data of anti-osteoporosis agents used in geriatric outpatients and other patients in our hospital so as to provide references for the clinical rational drug use. Methods：A retrospective analysis was carried out of the application of anti-osteoporosis agents in geriatric outpatients and in our hospital from 2010 to 2011 using the economic parameters such as DDDs, the ordering of drug consumption and daily defined cost. Results： Compared with 2010, the growth rate （62.37%） of the total amount of anti-osteoporosis drug consumptions was greater than that of other drugs （7.90%） in 2011. The clinical applications of bisphosphonates and calcium preparations were relatively stable, but the proportions declined. The growth rate of vitamin D and its active metabolite and calcitonin drugs in outpatients increased greatly. Good synchronous data of the consumption sum and DDDs in geriatric outpatients was obtained and the treatment cost was more reasonable. However the synchronous data of the consumption sum and DDDs in the patients of whole hospital was not satisfactory. The highest DDDs and sales amount of bisphosphonates and active vitamin D were showed which were used in geriatric outpatients and the whole hospital. The DDDs of alfacalcidol was obviously higher than that of calcitriol. Comparative advantage of pharmacoeconomics was proved in patient’s long-term application of the drugs, which was helpful to improve the compliance with medication in patients. Conclusion：The pharmacoeconomic analysis of anti-osteoporosis agents and the investigation of drug use tendency should be aimed at clinical situation. It can be more reflective of clinical rationality of medication to collect the data from professional departments during the analysis of drugs for related disease therapy.